Clinical trial
Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies
NCT00246103 · H. Lee Moffitt Cancer Center and Research Institute, Other · Completed
Key facts
| NCT number | NCT00246103 |
|---|---|
| Title | Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies |
| Official title | Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies |
| Lead sponsor | H. Lee Moffitt Cancer Center and Research Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH Pfizer Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms, Advanced |
| Intervention type | Drug |
| Interventions | Valproic acid, Epirubicin, 5-fluorouracil, Cyclophosphamide. |
| Enrollment | 82 |
| Start date | Mar 1, 2004 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Oct 31, 2005 |
| Last update posted | Feb 23, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: